ES / EN
- August 18, 2022 -
No Result
View All Result
OnCubaNews Needs You
OnCubaNews
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
OnCubaNews
ES / EN
ADVERTISEMENT
Home Cuba

Clinical trial in people convalescing from COVID-19 carried out in Cuba

The study uses the Soberana 01 vaccine candidate, the first to receive authorization in Cuba for tests on human beings, and seeks to “stimulate protective levels of neutralizing antibodies against possible reinfection.”

by OnCuba Staff, OnCuba editorial staff
January 26, 2021
in Cuba
0
Photo: Ismael Francisco/Cubadebate/Archive.

Photo: Ismael Francisco/Cubadebate/Archive.

Cuba is carrying out a clinical trial in people convalescing from COVID-19, who had a minor clinical picture or were asymptomatic, the official media reported.

The study uses the Soberana 01 vaccine candidate, the first to receive authorization in Cuba for tests on human beings, and seeks to “stimulate protective levels of neutralizing antibodies against possible reinfection,” Prensa Latina (PL) agency reported.

The agency recalled that “globally there are cases of people infected with this coronavirus who were reinfected, even with much more acute and serious forms of the disease,” which is why the trial that is taking place on the island “also seeks to protect this risk group.”

The test began on January 9 at the Institute of Hematology and Immunology and involves 30 volunteers, aged 19 to 59, “who were in contact with the virus and currently have a negative PCR.” These people received a single dose of the vaccine on day 16 and “from that moment on, they are being closely monitored through doctor’s offices and direct contact with the researchers.”

#Soberana01: El ensayo comenzó el pasado día 9 de enero con reclutamiento de 30 voluntarios entre 19 y 59 años de edad, y continuó con la vacunación el 16 de enero. Ahora se realiza consulta de seguimiento, para evaluar la respuesta inmune.#CienciaCubanahttps://t.co/tT02RkVdN0

— Instituto Finlay de Vacunas (@FinlayInstituto) January 24, 2021

Dr. Rolando Ochoa, a specialist in Immunology at the Finlay Vaccine Institute, explained that the formulation of Soberana 01 used in the test “is simpler and safer, according to the characteristics of the population group under study.”

Related Posts

Wholesale store for private restaurants in Havana, 2020. Photo: Alexandre Meneghini/REUTERS.

Cuba allows foreign investment in wholesale and retail trade

August 18, 2022
Photo: Otmaro Rodriguez

The visible traces of an extinguished fire

August 17, 2022
Cubans waiting for paperwork prior to traveling. Photo: Kaloian.

Cuba: measures making non-commercial imports more flexible come into force

August 16, 2022
Container terminal of the Mariel Special Development Zone, in Cuba. Photo: @ZEDMarielCuba/Twitter/Archive.

Cuba’s Mariel Special Development Zone: when promises aren’t kept

August 15, 2022

The expert argued that the vaccination was carried out in people convalescing from the disease, “who have low levels of neutralizing antibodies and, therefore, may be susceptible to reinfection,” Granma newspaper noted in this regard.

For his part, Dr. Arturo Chang, a specialist at the Institute of Hematology and Immunology, said that the study follows “the premise that these people were already vaccinated naturally (through contact with the virus), which is why this dose would be a boost to the individual’s immunity.”

The also principal investigator of the trial, which lasts for 28 days, explained that, “although what is conventional in phase I trials is that healthy and young people are chosen, the difference with this is that, when working with a population that already was in contact with the virus, it made it possible to include volunteers with some chronic pathology, but who are compensated.”

In addition, he specified, quoted by Granma, that “a second premise is related to the fact that the percentages of inhibition of antibodies against SARS-CoV-2 are relatively low, that is, that the person has not been immunized against the virus.” For this reason, he said “this trial is a novelty around the world, since the research has focused on the population sector that has not become ill.”

Chang stated that so far “there are no serious adverse events” and said that “if positive results are achieved in this phase, they will probably go on to a clinical trial with a larger number of subjects to evaluate the immunogenicity, efficacy and effectiveness of the product.”

Cuba has to date four COVID-19 vaccine candidates in the testing phase in humans: Soberana 01 and 02, both from the Finlay Institute, and Mambisa and Abdala, from the Center for Genetic Engineering and Biotechnology. Of these, Soberana 02 is the most advanced as it is already developing its phase II and Cuban scientists are confident that it can soon move on to phase III and be used in mass vaccination. To do this, they hope to produce 100 million doses this year.

Authors

OnCuba Staff, OnCuba editorial staff
Tags: coronavirus in CubaCuban scienceCuban vaccine against COVID-19
Previous Post

Coronavirus in Cuba: January sets another record for daily infections with 786 reported today

Next Post

January already worst month for Cubans due to coronavirus

OnCuba Staff

OnCuba Staff

OnCuba Staff

OnCuba Staff

Next Post
Cuba Street, in Havana. Photo: Otmaro Rodríguez.

January already worst month for Cubans due to coronavirus

Cuban Abdala vaccine candidate against COVID-19. Photo: Agencia Cubana de Noticias (ACN).

Favorable results of Cuban COVID-19 vaccine candidate

People connected to the internet at the entrance of a point of sale. Photo: Otmaro Rodríguez

U.S. restrictive policies on Cuban remittances: effects on families and emerging private sector

Leave a Reply Cancel reply

The conversation here is moderated according to OnCuba News discussion guidelines. Please read the Comment Policy before joining the discussion.

Your email address will not be published. Required fields are marked *

ADVERTISEMENT

Most Read

  • Cubans waiting for paperwork prior to traveling. Photo: Kaloian.

    Cuba: measures making non-commercial imports more flexible come into force

    12 shares
    Share 5 Tweet 3
  • Cuba’s Mariel Special Development Zone: when promises aren’t kept

    11 shares
    Share 4 Tweet 3
  • Environmental disaster and metadiplomacy. Alternatives for U.S.-Cuba relations?

    9 shares
    Share 4 Tweet 2
  • Cuba: purchase of foreign currency from population announced

    35 shares
    Share 14 Tweet 9
  • One week after the fire (+Videos)

    6 shares
    Share 2 Tweet 2

Most Commented

  • The new U.S. Chargé d'Affaires in Havana, Benjamin Ziff. Photo: Archive.

    Biden Administration appoints new charge d’affaires to head embassy in Havana

    14 shares
    Share 6 Tweet 4
  • The ruins of rural Cuba: little known historical relics.

    33 shares
    Share 13 Tweet 8
  • Tragedy: two Cubans die, 10 disappear and eight survive when boat capsizes south of Key West

    15 shares
    Share 6 Tweet 4
  • What foods can be brought to Cuba and what imports are forbidden?

    185 shares
    Share 74 Tweet 46
  • Roberlandy Simon: I am still a Cuban

    2 shares
    Share 1 Tweet 1
  • About us
  • Work with OnCuba
  • Terms of use
  • Privacy Policy
  • Moderation policy for comments
  • Contact us
  • Advertisement offers

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

No Result
View All Result
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

Go to mobile version